Modjtahedi Sara P, Modjtahedi Bobeck S, Mansury Ahmad M, Selva Dinesh, Douglas Raymond S, Goldberg Robert A, Leibovitch Igal
Division of Orbital and Ophthalmic Plastic and Reconstructive Surgery, and the Department of Ophthalmology, Jules Stein Eye Institute, David Geffen School of Medicine at University of California Los Angeles (UCLA), Los Angeles, CA 90095-7006, USA.
Drugs. 2006;66(13):1685-700. doi: 10.2165/00003495-200666130-00003.
Thyroid eye disease (TED), which affects the majority of patients with Grave's disease, is associated with significant ophthalmic morbidity. In patients with mild disease, supportive treatment with lubricating medication can be sufficient. However, in patients with severe TED and disfiguring proptosis or sight-threatening neuropathy, more aggressive medical or surgical interventions are necessary. Corticosteroids remain the preferred pharmacological treatment modality in the majority of patients with an active inflammatory component. Other immunosuppressive drugs in combination with corticosteroids may be helpful in patients with corticosteroid-resistant TED. Newer agents such as somatostatin analogues have not shown to be of significant clinical benefit; however, initial studies on the use of antioxidants and cytokine antagonists are encouraging.
甲状腺眼病（TED）影响大多数格雷夫斯病患者，会导致严重的眼部病变。对于轻度疾病患者，使用润滑药物进行支持性治疗可能就足够了。然而，对于患有严重甲状腺眼病且有毁容性眼球突出或威胁视力的神经病变的患者，则需要更积极的药物或手术干预。在大多数有活动性炎症成分的患者中，皮质类固醇仍然是首选的药物治疗方式。其他免疫抑制药物与皮质类固醇联合使用可能对皮质类固醇抵抗性甲状腺眼病患者有帮助。生长抑素类似物等新型药物尚未显示出显著的临床益处；然而，关于使用抗氧化剂和细胞因子拮抗剂的初步研究令人鼓舞。
